GoodRx Holdings (GDRX) Cost of Revenue (2019 - 2026)

GoodRx Holdings' Cost of Revenue history runs 8 years deep, the most recent figure standing at $81.1 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 4.13% year-over-year to $81.1 million; the TTM figure through Mar 2026 stood at $54.1 million (down 89.61% YoY), while the FY2025 annual figure was $57.6 million, down 84.31% from the prior year.
• Cost of Revenue came in at $81.1 million for Q1 2026 at GoodRx Holdings, up from -$195.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $331.1 million in Q4 2024 to a low of -$195.3 million in Q4 2025.
• A 5-year average of $92.1 million and a median of $84.5 million in 2025 frame the typical range for Cost of Revenue.
• On a YoY basis, Cost of Revenue climbed as much as 614.93% in 2025 and fell as far as 159.0% in 2025.
• GoodRx Holdings' Cost of Revenue stood at $309.9 million in 2022, then slipped by 6.56% to $289.6 million in 2023, then rose by 14.34% to $331.1 million in 2024, then tumbled by 159.0% to -$195.3 million in 2025, then soared by 141.49% to $81.1 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $81.1 million, -$195.3 million, and $83.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison